Managed
Care Perspectives on Menopause-Associated Vasomotor Symptoms: An Opportunity
to Control Costs and to Improve Quality of Preventive Care
Please review the following information and click "continue" at
the bottom of this screen to enter the activity.
Release
Date: January 2008
Expiration Date: January 2009
Target Audience and Goal
The goal of this presentation is to educate managed
care pharmacists and health care professionals about the gender differences
in resource utilization and quality of care, highlighting how the treatment
of vasomotor symptoms may be impacted by such differences and the opportunity
to improve the overall quality of care in this population.
Learning
Objectives
Upon completion of this activity, participants should
be able to:
- Explain differences in resource utilization and healthcare expenditures
incurred by women and men.
- Identify gaps in quality of preventive care for women, especially at the
time of menopause.
- Describe the impact of menopause-associated vasomotor symptoms on managed
care organizations, employers, and patients.
- Identify opportunities for managing costs and quality of care in relation
to the management of vasomotor symptoms.
Faculty
Gary Owens, MD
President
Gary Owens Associates
Speaker Disclosure
of Commercial Affiliations
The speakers for this continuing education activity have been asked to disclose
any significant financial interests, relationships, or affiliations they may
have with commercial entities whose products, devices or services may be discussed
in their presentations. Participants have the responsibility to assess the impact
(if any) of the disclosed information on the educational value of the activity.
The speaker has been offered a modest honorarium from the accredited provider
for their participation in this activity.
Dr. Owens has disclosed that he is a consultant to Amgen, Wyeth, Lilly, Novartis,
Ortho-Biotech, Collagenex and Genentech.
Product Disclosure
Some products or procedures discussed in this activity may be investigational
in nature. All speakers participating in this activity are expected to disclose
the approved or investigational status, related to menopause, of all agents
under discussion.
Accreditation
The Philadelphia College of Pharmacy is accredited by the Accreditation
Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity (056-000-08-003-H01-P) is acceptable for 1.0 continuing
education credits (0.1 CEUs).
Requirements for Credit
Credit will be awarded at no cost to participants who successfully complete
the activity, learning assessment (>70%) and activity evaluation form
online. A statement of credit will be available immediately upon completion
of the activity.
Disclaimer
The opinions expressed in Managed Care Perspectives on Menopause-Associated
Vasomotor Symptoms: An Opportunity to Control Costs and to Improve Quality
of Preventive Care are those of the speakers and do not necessarily
reflect those of the grantor or publisher. The provider does not approve
or endorse any particular product(s). This activity is not meant to serve
as a guideline for patient management; primary references and full prescribing
information should be consulted.
Commercial
Support
Supported
by an educational grant from Wyeth Pharmaceuticals.
Developed
and managed by Advanced Concepts Institute, Philadelphia College of Pharmacy
at University of the Sciences in Philadelphia.
SOFTWARE REQUIREMENTS
|
